Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized tamoxifen dosing: can a PET scan show the way?

NCT ID NCT04174352

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This pilot study tests whether a special PET scan (FES-PET/CT) can help doctors find the best dose of tamoxifen for people with metastatic breast cancer that has an ESR1 mutation. These mutations can make standard tamoxifen doses less effective. The study will enroll 12 participants and use the scan to measure how well tamoxifen blocks estrogen receptors at different dose levels. The goal is to identify the optimal dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tamoxifen
What this could lead to
If successful, this could show how to personalize tamoxifen dosing for patients with ESR1 mutations, potentially improving treatment effectiveness.
What could go wrong
This is a very small, early-phase pilot study with only 12 participants. It is designed to find the right dose, not to prove the treatment works, so results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERΑ+ BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERΑ+ BREAST CANCER ESR1 GENE MUTATION

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

  • Wisconsin Oncology Network (WONIX) sites

    NOT_YET_RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.